Previous clinical studies in humans (Wolf et al., 2013) and translational experiments in mice (Farrow et al., 2011), as well as isolated osteoblast/osteocyte cells (Noonan et al., 2021), have also shown that FGF23 is driven by anemia/hypoxia (Clinkenbeard et al., 2019). This evidence concerns the gene FGF23 and anemia.